Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Completes Acquisition of TissueInformatics

NEW YORK, March 12 (GenomeWeb News) - Paradigm Genetics has closed its acquisition of TissueInformatics, the company said yesterday.


Paradigm will issue approximately 3.4 million shares of its common stock to TissueInformatics shareholders immediately, valued at about $4.5 million, based on yesterday's closing price of Paradigm. Depending on whether TissueInformatics reaches certain revenue targets and obtains new research contracts before the end of the year, Paradigm will offer shareholders another 2.7 million shares.


In addition, Paradigm will assume all of TissueInformatics' outstanding options and warrants, equivalent to approximately 385,000 shares of Paradigm's common stock if TissueInformatics reaches its milestones. All shares will be locked up for one year after the date of closing.


Paradigm, based in Research Triangle Park, said it will maintain TissueInformatics' facility in Pittsburgh, Pa. Following the acquisition, first announced in January, Paradigm has 212 employees in total.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.